2016
DOI: 10.1002/14651858.cd001750.pub4
|View full text |Cite
|
Sign up to set email alerts
|

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

Abstract: Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

8
193
0
6

Year Published

2017
2017
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 291 publications
(207 citation statements)
references
References 128 publications
8
193
0
6
Order By: Relevance
“…The live birth rate in a systematic review of 22 RCTs, conducted by Kolibianakis [3], was consistent with the findings reported by Al-Inany [2]. Another systematic review of 45 RCTs, conducted by Al-Inany in 2011 [4], reaffirmed the earlier results by the same author [2] with regard to the ongoing pregnancy and live birth rates and the incidence of severe OHSS. However, a review by Orvieto [5] stated that the ongoing pregnancy and live birth rates were significantly higher in the group treated according to the GnRH agonist long protocol compared to those treated with the GnRH antagonist and that the agonist protocol remained significantly better than the GnRH antagonist protocol.…”
Section: Introductionsupporting
confidence: 78%
See 1 more Smart Citation
“…The live birth rate in a systematic review of 22 RCTs, conducted by Kolibianakis [3], was consistent with the findings reported by Al-Inany [2]. Another systematic review of 45 RCTs, conducted by Al-Inany in 2011 [4], reaffirmed the earlier results by the same author [2] with regard to the ongoing pregnancy and live birth rates and the incidence of severe OHSS. However, a review by Orvieto [5] stated that the ongoing pregnancy and live birth rates were significantly higher in the group treated according to the GnRH agonist long protocol compared to those treated with the GnRH antagonist and that the agonist protocol remained significantly better than the GnRH antagonist protocol.…”
Section: Introductionsupporting
confidence: 78%
“…The ovarian response to COH is an important factor that affects the pregnancy outcome, and different ovarian responses would produce different effects on pregnancy. Among the above-described systematic reviews, only the 2011 study by Al-Inany [4] conducted an analysis of all included patients, as well as of low-response and polycystic ovary syndrome (PCOS) subgroups. For all patients, the clinical pregnancy rate was significantly lower with the GnRH antagonist treatment than with the GnRH agonist long protocol, whereas the clinical pregnancy rates in the low-response and PCOS subgroups did not significantly differ, suggesting that the same COH protocol would cause different pregnancy outcomes in patients with different ovarian responses.…”
Section: Introductionmentioning
confidence: 99%
“…Compared to the GnRH agonist long protocol, the GnRH antagonist protocol has the advantages of a shorter duration of stimulation, reduced gonadotropin dose requirements, a lower cycle cancellation rate, lower peak E 2 levels, and a lower incidence of OHSS. The ongoing pregnancy rate and live birth rate have been found to be comparable to those obtained using long GnRH agonist protocols [7181920]. While administering a GnRH antagonist in the midfollicular phase has the above advantages, it was found that follicular development showed poor synchronization (i.e., greater size heterogeneity among growing follicles during COS) compared to the GnRH agonist long protocol, resulting in fewer follicles being visible on the day of hCG administration and fewer oocytes being retrieved.…”
Section: Discussionmentioning
confidence: 95%
“…Compared to the older and more established long GnRH agonist protocol, the GnRH antagonist protocol is shorter and less expensive because less gonadotropins are usually needed for controlled ovarian hyperstimulation [1][2][3].The main advantage of GnRH antagonist protocols is reducing ovarian hyperstimulation (OHSS) without reducing live birth rates [1][2][3].…”
Section: Introductionmentioning
confidence: 99%